Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.34
KOOL's Cash to Debt is ranked higher than
58% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. KOOL: 2.34 )
Ranked among companies with meaningful Cash to Debt only.
KOOL' s Cash to Debt Range Over the Past 10 Years
Min: 2.34  Med: 1445.38 Max: No Debt
Current: 2.34
Equity to Asset 0.65
KOOL's Equity to Asset is ranked higher than
59% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. KOOL: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
KOOL' s Equity to Asset Range Over the Past 10 Years
Min: 0.65  Med: 0.81 Max: 0.88
Current: 0.65
0.65
0.88
F-Score: 2
Z-Score: -3.75
M-Score: -3.00
WACC vs ROIC
-4.42%
-37.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -91.08
KOOL's Operating margin (%) is ranked lower than
77% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. KOOL: -91.08 )
Ranked among companies with meaningful Operating margin (%) only.
KOOL' s Operating margin (%) Range Over the Past 10 Years
Min: -92.63  Med: -45.79 Max: -12.12
Current: -91.08
-92.63
-12.12
Net-margin (%) -155.82
KOOL's Net-margin (%) is ranked lower than
82% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. KOOL: -155.82 )
Ranked among companies with meaningful Net-margin (%) only.
KOOL' s Net-margin (%) Range Over the Past 10 Years
Min: -155.82  Med: -41.14 Max: -10.97
Current: -155.82
-155.82
-10.97
ROE (%) -55.52
KOOL's ROE (%) is ranked lower than
78% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. KOOL: -55.52 )
Ranked among companies with meaningful ROE (%) only.
KOOL' s ROE (%) Range Over the Past 10 Years
Min: -55.52  Med: -27.29 Max: -13.56
Current: -55.52
-55.52
-13.56
ROA (%) -36.71
KOOL's ROA (%) is ranked lower than
74% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. KOOL: -36.71 )
Ranked among companies with meaningful ROA (%) only.
KOOL' s ROA (%) Range Over the Past 10 Years
Min: -36.93  Med: -21.57 Max: -10.6
Current: -36.71
-36.93
-10.6
ROC (Joel Greenblatt) (%) -441.86
KOOL's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. KOOL: -441.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KOOL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -441.86  Med: -136.59 Max: -36.5
Current: -441.86
-441.86
-36.5
Revenue Growth (3Y)(%) -39.30
KOOL's Revenue Growth (3Y)(%) is ranked lower than
89% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. KOOL: -39.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
KOOL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.3  Med: -4.5 Max: 20.7
Current: -39.3
-39.3
20.7
EBITDA Growth (3Y)(%) 27.50
KOOL's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. KOOL: 27.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
KOOL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -39  Med: -8.6 Max: 27.6
Current: 27.5
-39
27.6
EPS Growth (3Y)(%) 25.80
KOOL's EPS Growth (3Y)(%) is ranked higher than
57% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. KOOL: 25.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
KOOL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -35.7  Med: -7.8 Max: 28.4
Current: 25.8
-35.7
28.4
» KOOL's 10-Y Financials

Financials (Next Earnings Date: 2016-11-16)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

KOOL Guru Trades in

Q4 2015

KOOL Guru Trades in Q4 2015

Jim Simons 57,029 sh (New)
» More
Q1 2016

KOOL Guru Trades in Q1 2016

Jim Simons Sold Out
» More
Q2 2016

KOOL Guru Trades in Q2 2016

Jim Simons 30,635 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with KOOL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:NVCN, AMEX:ELMD, NAS:MSON, OTCPK:DIZTF, OTCPK:BTCY, NAS:MGCD, OTCPK:TLTFF, NAS:CGNT, OTCPK:BSGM, NAS:SPAN, OTCPK:PHMZF, OTCPK:TITXF, OTCPK:AVMXF, OTCPK:ZMSPF, NAS:AMDA, OTCPK:VASO, OTCPK:QTVLF, NAS:MDVX, OTCPK:ARCRF, OTCPK:BLOZF » details
Traded in other countries:THRN.Germany,
Cesca Therapeutics Inc is engaged in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It develops and manufactures automated blood and bone marrow processing systems.

Cesca Therapeutics Inc formerly known as ThermoGenesis Corp, founded in 1986 in California. The Company is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine. It serves patients, physicians and partners through cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking markets. The Company offers SurgWerks, a therapeutic technology platform, in various stages of clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also offers CellWerks, an indication-specific device/protocol program for select applications in umbilical cord blood banking, bone marrow transplantation, and regenmed bioprocess markets. The Company complies under a variety of Good practices concerning operation of clinical cell manufacturing, processing, testing, and storage facilities, as well as patient safety, quality laboratory documentation, and quality cell processing and handling. It supports production of personalized medicine prescriptions and large scale batch processes. The Company has the ability to support various device prototyping and validation, typically required in a combination product. Its clinical research organization is specialized, in-hospital and cell therapy CRO.

Ratios

vs
industry
vs
history
P/B 0.38
KOOL's P/B is ranked higher than
99% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. KOOL: 0.38 )
Ranked among companies with meaningful P/B only.
KOOL' s P/B Range Over the Past 10 Years
Min: 0.17  Med: 1.56 Max: 20.46
Current: 0.38
0.17
20.46
P/S 0.76
KOOL's P/S is ranked higher than
88% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. KOOL: 0.76 )
Ranked among companies with meaningful P/S only.
KOOL' s P/S Range Over the Past 10 Years
Min: 0.36  Med: 1.66 Max: 22.83
Current: 0.76
0.36
22.83
EV-to-EBIT -1.87
KOOL's EV-to-EBIT is ranked lower than
99.99% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 22.51 vs. KOOL: -1.87 )
Ranked among companies with meaningful EV-to-EBIT only.
KOOL' s EV-to-EBIT Range Over the Past 10 Years
Min: -36.6  Med: -3.4 Max: 0.5
Current: -1.87
-36.6
0.5
EV-to-EBITDA -2.00
KOOL's EV-to-EBITDA is ranked lower than
99.99% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 16.88 vs. KOOL: -2.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
KOOL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -39.4  Med: -4 Max: 0.5
Current: -2
-39.4
0.5
Current Ratio 2.32
KOOL's Current Ratio is ranked higher than
50% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. KOOL: 2.32 )
Ranked among companies with meaningful Current Ratio only.
KOOL' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 5.24 Max: 12.49
Current: 2.32
1.67
12.49
Quick Ratio 1.67
KOOL's Quick Ratio is ranked higher than
51% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. KOOL: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
KOOL' s Quick Ratio Range Over the Past 10 Years
Min: 1.09  Med: 3.74 Max: 11.74
Current: 1.67
1.09
11.74
Days Inventory 156.35
KOOL's Days Inventory is ranked lower than
60% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. KOOL: 156.35 )
Ranked among companies with meaningful Days Inventory only.
KOOL' s Days Inventory Range Over the Past 10 Years
Min: 119.78  Med: 152.7 Max: 181.75
Current: 156.35
119.78
181.75
Days Sales Outstanding 96.96
KOOL's Days Sales Outstanding is ranked lower than
80% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. KOOL: 96.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
KOOL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.82  Med: 96.66 Max: 116.79
Current: 96.96
61.82
116.79
Days Payable 105.23
KOOL's Days Payable is ranked higher than
79% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. KOOL: 105.23 )
Ranked among companies with meaningful Days Payable only.
KOOL' s Days Payable Range Over the Past 10 Years
Min: 44.89  Med: 88.74 Max: 164.16
Current: 105.23
44.89
164.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -53.60
KOOL's 3-Year Average Share Buyback Ratio is ranked lower than
90% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. KOOL: -53.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KOOL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -53.6  Med: -11.9 Max: 0
Current: -53.6
-53.6
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.45
KOOL's Price/Median PS Value is ranked higher than
91% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. KOOL: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
KOOL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.34  Med: 3.13 Max: 11.66
Current: 0.45
0.34
11.66
Earnings Yield (Greenblatt) (%) -53.16
KOOL's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. KOOL: -53.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KOOL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -705.47  Med: 170.85 Max: 7391.6
Current: -53.16
-705.47
7391.6

More Statistics

Revenue (TTM) (Mil) $11.93
EPS (TTM) $ -7.01
Beta-1.46
Short Percentage of Float24.00%
52-Week Range $1.64 - 12.80
Shares Outstanding (Mil)9.79

Analyst Estimate

Jun17 Jun18 Jun19
Revenue (Mil $) 12 12 13
EPS ($) -1.18 -1.27 -1.27
EPS w/o NRI ($) -1.18 -1.27 -1.27
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for KOOL

Headlines

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: 2016 By the Numbers : September 28, 2016 Sep 28 2016
Cesca Therapeutics to Present & Exhibit at the ISCT North America 2016 Regional Meeting Sep 27 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits Sep 26 2016
CESCA THERAPEUTICS INC. Financials Sep 24 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Sep 21 2016
Edited Transcript of KOOL earnings conference call or presentation 20-Sep-16 9:00pm GMT Sep 20 2016
CESCA THERAPEUTICS REPORTS FOURTH QUARTER AND FISCAL 2016 YEAR END RESULTS Sep 20 2016
Cesca Therapeutics Reports Fourth Quarter and Fiscal 2016 Year End Results Sep 20 2016
Q4 2016 Cesca Therapeutics Inc Earnings Release - After Market Close Sep 20 2016
CESCA THERAPEUTICS TO REPORT FISCAL FOURTH QUARTER AND FULL YEAR 2016 FINANCIAL RESULTS AND PROVIDE... Sep 19 2016
CESCA THERAPEUTICS GRANTED TWO PATENTS FOR RAPID INFUSION OF AUTOLOGOUS BONE MARROW DERIVED STEM... Sep 19 2016
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem... Sep 19 2016
Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide... Sep 16 2016
Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw® Global Investment Conference Sep 08 2016
Arcadia Biosciences Names New Chief Financial Officer Sep 08 2016
Chinese stem-cell research company takes control of Rancho Cordova's Cesca Therapeutics Aug 26 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Aug 25 2016
CESCA THERAPEUTICS ANNOUNCES CONVERSION OF $12.5 MILLION IN SENIOR SECURED DEBT TO EQUITY Aug 25 2016
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity Aug 24 2016
Cesca Therapeutics raises $2.5 million in private placement of stock Aug 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)